The International Journal of Neuropsychopharmacology
September 1, 2026
K Kusudo, K Yonezawa, Sota Tomiyama et al.
Abstract Background Psilocybin, a prodrug metabolized to psilocin, a serotonin 2A receptor agonist, has reemerged as a promising therapeutic option for treatment-resistant depression (TRD). Clinical trials conducted mainly in North America and Europe have demonstrated that psilocybin administered with psychological support can produce rapid and sustained antidepressant effects with favorable...
The International Journal of Neuropsychopharmacology
September 1, 2026
K Yonezawa, K Kusudo, Sota Tomiyama et al.
Abstract Background Despite recent advances in the treatment of major depression, approximately 30% of patients show insufficient improvement with conventional antidepressants, a condition commonly referred to as treatment-resistant depression (TRD). Psilocybin is a classic psychedelic compound that has received renewed attention as a promising therapeutic candidate for TRD. Clinical trials...
The International Journal of Neuropsychopharmacology
September 1, 2026
Abstract Background Depressive disorders affect approximately 280 million people worldwide, with many patients finding existing treatments ineffective or limited by adverse effects. Growing evidence from community microdosing reports suggests that psychedelic therapies may help alleviate depressive symptoms. Among these, lysergic acid diethylamide (LSD) microdosing has shown particular promise...
The International Journal of Neuropsychopharmacology
September 1, 2026
Abstract Background As psychedelic therapies advance toward regulatory approval worldwide, significant questions arise about the adequacy of traditional evidence hierarchies for evaluating these complex interventions. Psychedelic-assisted therapies combine pharmacological, psychological, contextual, and phenomenological elements that challenge conventional randomized controlled trial (RCT)...
Human Psychopharmacology: Clinical and Experimental
September 1, 2026
José Norberto Vásquez-Bonilla
OBJECTIVE: This review critically examines psilocybin, with particular emphasis on its pharmacokinetics and pharmacodynamics, including its serotonergic, neuroplastic, and anti-inflammatory mechanisms. It integrates historical context, preclinical and clinical evidence, and evaluates emerging therapeutic potential, safety, microdosing practices, and pharmacological interactions. METHODS: A...
Medical Humanities
August 31, 2026
Daniel Laforest
In this review essay I outline how the current renaissance of psychedelics in mainstream discourses about medicine is spearheaded first and foremost by profit-oriented technomedical initiatives focusing on individual wellness, and how this very situation reinforces a problematic line of demarcation between the psychopharmaceutical approach to mental health, and the more classical approach that...
International Journal of Innovative Technologies in Social Science
August 31, 2026
Anna Szeszko, Weronika Maria Czernek, Magdalena Cichorzewska et al.
Psychedelic-assisted therapy has emerged as a prominent area for psychiatric investigation particularly with regards to treatment-resistant depression and Post Traumatic Stress Disorder (PTSD). The purpose of this narrative review was to outline the current body of research regarding psychedelic and psychedelic-like compounds in these two psychiatric conditions highlighting psilocybin-assisted...
CNS Drugs
August 26, 2026
Alana King, Morgan S. Hardy, Taeho Greg Rhee et al.
Despite the wide prevalence of mood disorders globally, there is a substantial unmet need for effective, mechanistically distinct treatments. Given that approximately 30% of individuals do not display adequate response to standard antidepressant therapies, the past 15 years have seen a shift away from traditional monoaminergic approaches toward glutamatergic and other novel mechanisms....
Psychoanalytic Inquiry
August 25, 2026
Nathan Gorelick
This article revisits Lacan’s skepticism toward the psychoanalytic value of drug-induced altered states of consciousness in light of the contemporary surge of scientific, therapeutic, and pharmacological investment in psychedelics. Beyond any prescription, interdiction, or theoretical insight, the author shows how Lacan offers a necessary ethical corrective to the use of psychedelics within the...
Zenodo (CERN European Organization for Nuclear Research)
August 25, 2026
Frederick A.P. van der Sypt
preprint
Abstract In contemporary, predominantly cognitively oriented society, many lack interoceptive literacy: the ability to recognize the underlying bodily signals of emotions, thoughts, and behavior. Because both clients and therapists are shaped by this societal framework, psychotherapeutic interventions risk remaining at a purely intellectual level, where cognitive restructuring occurs without...